Sangamo Biosciences, Inc. (SGMO) Tops Q2 EPS by 4c

Sangamo Biosciences, Inc. (NASDAQ: SGMO) reported Q2 EPS of ($0.10), $0.04 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $10.4 million versus the consensus estimate of $7.84 million.

For earnings history and earnings-related data on Sangamo Biosciences, Inc. (SGMO) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Vireo Growth completes acquisition of C21 Investments
• Arena Group to rename as Paradium.AI, ticker changing to PAAI